Boundless Bio
BOLD
35 hedge funds and large institutions have $11.8M invested in Boundless Bio in 2025 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 15 reducing their positions, and 10 closing their positions.
0.74% less ownership
Funds ownership: 43.72% → 42.98% (-0.74%)
19% less capital inflows, than outflows
Capital inflows: $716K | Capital outflows: $889K
20% less funds holding
Funds holding: 44 → 35 (-9)
53% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 15
90% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Stonepine Capital Management
Bend,
Oregon
|
+$355K |
| 2 |
Renaissance Technologies
New York
|
+$118K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$102K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$52.5K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$50.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Redmile Group
San Francisco,
California
|
-$397K |
| 2 |
Almitas Capital
Santa Monica,
California
|
-$172K |
| 3 |
Goldman Sachs
New York
|
-$64.6K |
| 4 |
Millennium Management
New York
|
-$57.1K |
| 5 |
Y-Intercept (HK)
Hong Kong
|
-$55.8K |
BOLD Hedge Fund Activity: Q3 2025 in Review
35 of the 7,656 institutional investors tracked by Wall St. Rank reported a position in Boundless Bio (BOLD) for Q3 2025, worth a combined $11.8M — up 20% from $9.9M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of BOLD and 1 opened new positions — a net loss of 9 holders — while 15 trimmed existing stakes and 7 added.
The largest buyer was Stonepine Capital Management, adding an estimated $355K. The largest seller was Redmile Group, cutting an estimated $397K.
- 35 institutional investors held Boundless Bio (BOLD) as of Q3 2025, down from 44 in Q2 2025.
- Funds reported $11.8M of Boundless Bio stock for Q3 2025, up 20% quarter-over-quarter.
- 1 fund opened new Boundless Bio positions in Q3 2025 and 10 closed out, a net change of -9 holders.
- The largest Boundless Bio buyer in Q3 2025 was Stonepine Capital Management, an estimated $355K added.
- The largest Boundless Bio seller in Q3 2025 was Redmile Group, an estimated $397K sold.
Based on aggregated 13F filings for Q3 2025.